Skip to main content


Editor's pick

Duvelisib offers treatment alternative for patients with CLL/SLL

Older man taking pill

The oral, dual inhibitor of phosphoinositide 3-kinase-δ and –γ duvelisib significantly delays disease progression or death compared with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, data from the DUO trial show.

ASCO 2018: Abi Race trial in prostate cancer

Lead author Daniel George discusses his team's findings of a greater and longer lasting treatment effect with abiraterone acetate and prednisone in Black than White men with metastatic castration-resistance prostate cancer (3:59). 

ASCO 2018: CARMENA trial in renal cell carcinoma

Arnaud Méjean presents the CARMENA trial findings, suggesting that cytoreductive nephrectomy may no longer be the standard of care for metastatic renal cell carcinoma in the era of sunitinib (4:21).

ASCO 2018: TAILORx trial in breast cancer

Joseph Sparano gives an overview of his team's findings regarding a 21-gene prognostic test that could help tailor treatment for women with early breast cancer (3:24).

ASCO 2018: IMPACT trial across multiple cancers

Apostolia Tsimberidou discusses the findings of the IMPACT study, looking at the survival benefits of matching targeted treatments to the genetic alterations of tumors across multiple cancer types (7:56).

19-10-2018 | Non-small-cell lung cancer | News | Article

ESMO 2018

Dual MET–EGFR inhibition promising for relapsed MET-high NSCLC

Combining the highly selective MET inhibitor tepotinib with gefitinib could benefit patients with non-small-cell lung cancer that has progressed on first-line treatment with an EGFR–tyrosine kinase inhibitor and has high levels of MET, suggest phase II trial results.


ESMO 2018; Munich, Germany; 19–24 October 2018

19-10-2018 | Lung cancer | News | Article

Adding plasma NGS testing to routine NSCLC management could aid targeted therapy delivery

Plasma-based next-generation sequencing may help to identify therapeutically targetable mutations in patients with metastatic non-small-cell lung cancer, suggests research published in JAMA Oncology.


JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.4305

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.4304

19-10-2018 | Oncology | News | Article

Post-induction PET predicts outcome in follicular lymphoma

Patients with follicular lymphoma who achieve a positron emission tomography-determined complete response to induction immunochemotherapy have a significantly better prognosis than those with a non-complete response, research shows.


Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30618-1

18-10-2018 | Oncology | Main feed | News

Long-term PFS benefits of pelvic irradiation shown in prostate cancer

An updated analysis of the NRG/RTOG 9413 trial shows that the benefits of whole pelvic radiotherapy plus neoadjuvant hormonal therapy persist in the long term in patients with intermediate- or high-risk localised prostate cancer.


Lancet Oncol 2018; doi:10.1016/ S1470-2045(18)30528-X
Lancet Oncol 2018; doi:10.1016/ S1470-2045(18)30588-6

Optimal Radiation–ADT Regimen Still Unclear For Intermediate–High-Risk Localised PC

After more than 8 years of follow-up, researchers favour whole-pelvis radiotherapy plus neoadjuvant hormone therapy for the treatment of men with intermediate- and high-risk localised prostate cancer  Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

Twitter Icon Follow medwireNews

Click here
image credits